NANCHANG, China, Jan 20 (Bernama-AsiaNet) — On January 15, Jemincare Group, a Chinese pharmaceutical company, announced that it has initiated the phase I clinical trial of anti-SARS-CoV-2 neutralizing antibody (JMB2002).
Preclinical studies of JMB2002 including pharmacology and toxicity were carried out systemically. The drug metabolism, safety and efficacy were well performed. In early studies, it was found that JMB2002 could effectively neutralize live virus infection of Vero E6 cells. What’s more, JMB2002 showed potent binding and blocking activities to the spike glycoproteins of mutant viruses.
